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To the editor, 
 
 
Inflammatory linear verrucous epidermal naevus (ILVEN) is a rare skin condition. 
Classically it presents at birth or within the first year of life, frequently progressing 
during early childhood.  Diagnostic criteria are erythematous verrucous 
hyperkeratosis in a fine and whorled Blaschko-linear pattern, intense pruritus, early 
age of onset, histological features, and resistance to treatment(Morag and Metzker, 
1985).  The cause of ILVEN has been unknown, however a single case of mosaicism 
in gene GJA1 has recently been reported (Umegaki-Arao et al., 2017).  We sought to 
investigate the genetics of ILVEN with a view to new therapeutic angles. 
 
Fifteen children with ILVEN and six normal controls (from surgery where excess 
normal skin was available) were recruited with written informed consent and 
Research Ethics Committee approval from Great Ormond Street Hospital Research 
and Development office. The patients’ parents/guardians consented to the 
publication of the patient images. DNA and RNA were extracted from skin biopsies 
of affected tissue, and DNA from blood by standard methods, and affected skin 
keratinocytes cultured and immortalised where possible (Lenti-HPV-16 E6/E7 Virus).   
Deep whole exome sequencing (WES) of blood and affected skin was performed on 
patient samples and data analysed using an optimised bioinformatic pathway for 
the detection of low-level somatic variants as previously published (Al-Olabi et al., 
2018). Pathogenic GJA1 variants were not found in any patient.  Clinical and 










Heterozygous missense variants in gene Caspase Recruitment Domain Family 
Member 14 (CARD14) were detected in 2/15 patients (Fig.2C-D).  In both patients 
the allelic load was compatible with that of a mosaic variant – in patient 1 the 
variant was present at 20% in both blood and DNA extracted directly from a whole 
punch biopsy of affected skin (c.356T>A, p. (M119K)), and in patient 2 at 1% from 
DNA extracted directly from the epidermis of affected skin and undetectable in 
blood (4/313 reads in skin, c.277A>G, p.(K93E)).  We had intended that WES of the 
epidermis in patient 2 might have increased the mutant allele load, however this 
was not the case, and the 1% load may have been due to mainly cornified epidermis 
being sequenced. Both variants were, however, convincing on WES raw data, and 
both were clearly confirmed by Sanger sequencing (Fig.2E-F).  The missense variant 
in patient 1 affects the same codon as one previously published in a non-mosaic 
state causing pityriasis rubra pilaris (Lwin et al., 2018), supporting its likely 
pathogenicity in vivo, and also supported by in silico predictions (SIFT Tolerated, 
Polyphen2 Benign, Mutation Taster Disease Causing, PROVEAN Neutral, CONDEL 
Neutral, CADD score 22.6) .The variant in patient 2 is predicted overall likely 
pathogenic in silico (SIFT Tolerated, Polyphen2 Probably Damaging, Mutation Taster 
Disease Causing, PROVEAN Neutral, CONDEL Deleterious, CADD score 24.1), and as 
it was to our knowledge previously unreported, we went on to characterise its 
functional effects.  Cultured patient keratinocytes from patient 2 were used to 
model the variants in the most biologically-similar manner.  Additionally, the patient 
2 variant was modelled in a keratinocyte cell line (SVK14) that was transfected 
(Lipofectamine 2000) with CARD14 wild-type and mutant (c.277A>G) pcDNA3.1-HA 









and it was not deemed ethical to take further biopsies from a child for this purpose 
only. 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) demonstrated a 
significant increase in IL12A and IL23A in cultured patient keratinocytes and SVK14 
cells transfected with the mutant CARD14 construct compared to identically-
handled keratinocytes from grouped normal controls (Fig.2G) and SVK14 cells 
transfected with the wild-type CARD14 construct (Fig.2H). This was further 
validated at protein level by IL12/IL23 p40 ELISA (Fig.2M-N) (Invitrogen, United 
States). In addition, WST-1 assay (Sigma-Aldrich, USA) demonstrated a significant 
increase in proliferation rate in patient keratinocytes and SVK14 cells transfected 
with the mutant CARD14 construct (Fig.2I-J).  A significant increase in NF-B p65 
subunit activity was demonstrated by ELISA in nuclear extracts from SVK14 cells 
transfected with the mutant CARD14 construct (Fig.2L) but not in patient 
keratinocyte nuclear extracts (Fig.2K) (Abcam, United Kingdom), potentially due to 
the less physiological model of overexpression in the cell line model. 
 
Inherited (non-mosaic) heterozygous mutations in CARD14 were recently described 
as rare causes of psoriasis(Jordan et al., 2012) and pityriasis rubra pilaris 
(PRP)(Fuchs-Telem et al., 2012).  Variants affecting certain domains of CARD14 were 
initially described as leading to activation of NF-B in the skin(Fuchs-Telem et al., 
2012).  However, differences between wild type and variant CARD14 effects on NF-
B are modest (Li et al., 2015), and not all pathogenic variants increase activation of 









(aa 15-107) (Israel and Mellet, 2018) such as that in patient 2.  Treatment of 
patients with germline CARD14 variants with Ustekinumab has been highly 
successful (Eytan et al., 2014, Lwin et al., 2018), however direct measurement of the 
effect of CARD14 variants on IL12 and IL23 expression has not previously been 
performed.  Our findings suggest that IL12 and IL23 could be increased by CARD14 
variants in a non-NF-B dependent manner.  
 
Patient 1 had been resistant to multiple therapies (cyclosporine, acitretin, oral 
prednisolone), and she had faltering growth (height and weight below the 0.4th 
centile by three years of age; birth weight 50th- 75th centile).  With hospital drug and 
therapeutics committee approval we started treatment at the age of six with 
Ustekinumab (0.75mg/kg/ dose at 0 and 1 months, 3 monthly thereafter, as per 
psoriasis protocol).  She has had a dramatic and sustained improvement in her skin, 
now 20 months into treatment, but has required an increase to 8-weekly dosing to 
maintain effect between doses. She also exhibited catch-up growth, with height and 
weight improving from the <0.4th to 2nd-9th percentile within three months (Fig.1D-
F), and no adverse effects.   Patient 2 is younger and less symptomatic (Fig.1G-J) 
and has not required treatment. 
 
Historically there has been debate about clinical and histopathological similarities of 
ILVEN to Congenital Hemidysplasia, Ichthyosiform Erythroderma and Limb Defects 
(CHILD) syndrome, and to psoriasis(Happle, 1991, Ito et al., 1991, Moss and Burn, 









genetic heterogeneity in ILVEN, and that the term ILVEN is a clinical description 
rather than a single histopathological or genetic entity.   
 
We identify here that heterozygous missense variants in CARD14 are a recurrent 
cause of this phenotype, leading to successful targeted medical therapy in one 
patient.  Indications for treatment should be made on an individual patient basis.  
Genetic counselling should be considered in ILVEN, as in these cases it could be 
passed on as PRP or psoriasis. These findings underline the power of molecular 
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Figure 1. Clinical features of CARD14-mosaic ILVEN and dramatic response to 
targeted therapy in one patient.  Patient 1 pre-treatment (A-C) and 3 months post 
commencing Ustekinumab (D-F), showing dramatic reduction in erythema and 
hyperkeratosis. Patient 2 pre-treatment showing predominantly left-sided Blaschko-
linear inflammatory, hyperkeratotic skin lesions at one year (G, I) and 4 years (H, J).  
The patients’ parents/guardians consented to the publication of the patient images. 
 
 
Figure 2.   
Histological features and mosaic genetic variants in CARD14-ILVEN. Patient 1 – (A, 
C, E), patient 2 - (B, D, F, G, H, I, J, K,L,M,N).   
(A, B) Histology demonstrating alternating orthokeratosis (white arrow) and 
parakeratosis (black arrow) in patient 1, with generalised disruption of cornification 
in patient 2.  Histological variability between ILVEN samples (from clinical diagnosis) 
was found to be very broad.  (C, D) Whole exome sequencing visualised in the 
Integrative Genomics Viewer (Broad Institute) demonstrates mosaic CARD14 
missense variants c. 356T>A, p. (M119K) (patient 1, C), and c.277A>G, p.(K93E) 
(patient 2, D).  (E-F) Sanger sequencing chromatograms confirm the variants. 
Cultured patient keratinocytes and SVK14 cells transfected with a mutant CARD14 
construct express increased IL12 and IL23 at mRNA and protein level, proliferate 









demonstrating a significant increase in IL12A and IL23A in cultured keratinocytes 
from affected skin from patient 2 and in SVK14 cells transfected with the mutant 
CARD14 construct in comparison to control patient keratinocytes (n=3) and SVK14 
cells transfected with the wild-type CARD14 construct, respectively .Mean relative 
gene expression of five replicates per patient sample and duplicates per SVK14 
sample was calculated with standard deviation. (I, J) WST-1 proliferation assay 
showing a proliferation increase in keratinocytes cultured from patient 2 and in 
SVK14 cells transfected with the mutant CARD14 construct compared to control 
patient keratinocytes (n=3) and SVK14 cells transfected with the wild-type CARD14 
construct respectively, measured at 450 nm after two and four hours. The 
keratinocytes were cultured for 8 days prior to proliferation measurement.  Mean 
absorbance of five replicates is shown with standard deviation.  (K) Nuclear extracts 
from patient 2 keratinocytes do not show a difference in NF-B p65 activity when 
compared to control patient keratinocytes (n=6). (L) Nuclear extracts from SVK14 
cells transfected with the mutant CARD14 construct show an increase in NF-B p65 
activity when compared to SVK14 cells transfected with the wild-type CARD14 
construct. Mean absorbance of triplicates for patient/control keratinocytes and 
positive control is shown with standard deviation. (M,N) Patient 2 keratinocytes and 
SVK14 cells transfected with the mutant CARD14 construct have significantly 
increased levels of IL12 and IL23 secreted in the supernatant compared to control 
keratinocyte cell lines (n=4) and SVK14 cells transfected with the wild-type CARD14 
construct, respectively . Mean absorbance of triplicates is shown with standard 
deviation. All p-values were calculated by Students t-test using Prism v7.0 









staining of SVK14 cells transfected with CARD14 wild-type and mutant pcDNA3.1-HA 


























 Patient 1 Patient 2 
Age of onset  11 months 
 
1 year 
Lesion type Blaschko-linear erythematous, hyperkeratotic, 
pruritic  
Blaschko-linear erythematous, hyperkeratotic 
Lesion distribution Generalised 
 
Appeared on left thumb at 4-6 weeks of age 
Lesion extent Facial, truncal and all limbs 
 
Facial, truncal, all limbs 
Unilateral / Bilateral 
 
Bilateral Initially unilateral on the left side, progressed to bilateral  
Palmoplantar involvement (Y/N) and 
which type 
Diffuse palmoplantar keratoderma Linear palmoplantar keratoderma in continuity with arm lesions 
 
 
Table S1: Detailed clinical features of patients 1 and 2.  
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